Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 91 Neoplasm Metastasis 24 Neoplasms 14 Brain Neoplasms 13 Prostatic Neoplasms 10 Endometrial Neoplasms 10 Carcinoma, Non-Small-Cell Lung 10 Ovarian Neoplasms 7 Glioblastoma 7 Glioma 6 Triple Negative Breast Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 5 Head and Neck Neoplasms 5 Colorectal Neoplasms 5 Sarcoma 4 Recurrence 4 Pancreatic Neoplasms 4 Lymphoma, Non-Hodgkin 4 Sarcoma, Ewing 3 Osteosarcoma 3 Neoplasms by Site 3 Multiple Myeloma 3 Meningioma 3 Melanoma 3 Carcinoma, Renal Cell 3 Breast Diseases 3 Unilateral Breast Neoplasms 2 Rhabdomyosarcoma 2 Rhabdoid Tumor 2 Oligodendroglioma 2

Interventions

Cyclophosphamide 22 blinatumomab 18 Cytarabine 15 fludarabine 13 Azacitidine 12 venetoclax 10 fludarabine phosphate 10 Rituximab 8 Lenalidomide 7 Dexamethasone 7 Methotrexate 6 Daunorubicin 6 Mercaptopurine 5 daratumumab 4 Whole-Body Irradiation 4 Vincristine 4 Melphalan 4 Idarubicin 4 Etoposide 4 Busulfan 4 pembrolizumab 3 obinutuzumab 3 Radiotherapy 3 Maintenance 3 Immunotherapy, Adoptive 3 Imatinib Mesylate 3 Granulocyte Colony-Stimulating Factor 3 Drug Therapy 3 Cladribine 3 Asparaginase 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Neoplasm, Residual × abemaciclib × Clear all

NCT05708235 2026-03-05

MiRaDoR

MedSIR

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡